Early diagnosis of pregnancy-associated heart disease linked to better outcomes

November 16, 2019

PHILADELPHIA -- Women who are diagnosed with peripartum cardiomyopathy (PPCM) during late pregnancy or within a month following delivery are more likely to experience restored cardiac function and improved outcomes compared to those who are diagnosed later in the postpartum period, according to a new study from Penn Medicine. The findings underscore the need for increased awareness and monitoring of heart failure symptoms, particularly among black women, who, on average, are diagnosed significantly later than white patients, researchers found.

Authors say the findings, which will be published in Hypertension and presented at the American Heart Association's 2019 Scientific Sessions, may explain the striking disparities in outcomes between white and black patients with PPCM. In a previous study, published in JAMA Cardiology, the team found black women were only about half as likely to return to normal levels of cardiac function and took twice as long to do so.

"Our findings demonstrate that important racial disparities exist not only in the outcomes of patients with PPCM, but in the timing of diagnosis and baseline level of cardiac function," said the study's lead author Jennifer Lewey, MD, MPH, director of the Women's Cardiovascular Health Program and co-director of the Pregnancy and Heart Disease Program at Penn Medicine. "Cardiomyopathy is the leading cause of maternal mortality in the postpartum period, and while we recommend increased monitoring for peripartum cardiomyopathy in all patients, it's particularly important in black women. Earlier diagnoses of PPCM may help to prevent the poor outcomes and expedite their recovery to normal cardiac function."

PPCM, which affects at least one in 2,000 pregnancies in the United States, is a rare, potentially life-threatening form of heart failure in which the heart muscle becomes weak--often during the final month of pregnancy or in the first few months after delivery. Although the majority of patients, about 60 to 70 percent, experience a recovery to normal cardiac function, about 13 percent of patients experience severe, persistent cardiac dysfunction and can require a heart transplant or left ventricular assist device (LVAD), a mechanical pump that helps the left ventricle pump blood to the rest of the body.

Hypertensive disorders of pregnancy (HDP), such as gestational hypertension (high blood pressure noted in the latter part of pregnancy) and preeclampsia (a dangerous complication characterized by high blood pressure), are the strongest risk factors for PPCM. Previous studies have noted that patients with HDP and, ultimately, PPCM may fare better than those who do not develop HDP prior to PPCM. The studies suggest that if HDP contributes to the development of PPCM, the resolution of postpartum high blood pressure and restoration of normal blood vessel formation could accelerate one's recovery to normal cardiac function. However, several studies have demonstrated that no such relationship exists.

To further examine how HDP and the timing of diagnosis impact patient outcomes, the Penn team conducted a retrospective study of 220 patients diagnosed with PPCM. Although women with HDP are diagnosed with PPCM earlier in the postpartum period, researchers found that women with HDP and PPCM experienced similar rates of left ventricular ejection fraction (LVEF) as those without HDP (68 percent and 63 percent, respectively). However, they found that patients who were diagnosed with PPCM more than a month after the delivery had significantly lower rates of cardiac recovery than those who were diagnosed earlier (54 percent vs. 70 percent). Patients who received an early diagnosis generally had higher baselines of cardiac function, likely contributing to the improved outcomes, authors suggest.

Additionally, researchers found that the majority of white patients with PPCM and HDP were diagnosed within a week of delivery. However, black patients with PPCM and HDP were most likely to be diagnosed between one and five months postpartum, with a small percentage diagnosed even beyond the five-month mark.

"While we are still investigating the factors--such as genetics and socioeconomic status--that lead to later diagnosis in this population, we hope our findings help to increase awareness of the need for proactive monitoring," said the study's senior author Zoltan Arany, MD, PhD, a professor of Cardiovascular Medicine at Penn.

Lewey will present her research at 1:30 pm ET on Saturday, November 16, in Zone 2 of the Science and Technology Hall at the Pennsylvania Convention Center in Philadelphia.
-end-
The work was supported, in part, by grants from the National Institutes of Health (NIH) (K12HD085848 and R01HL126797) and a NIH CTSA SPIRIT award. Additional Penn authors include Lisa D. Levine, Michal A. Elovitz, and Olga C. Irizarry.

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $425 million awarded in the 2018 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center--which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report--Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation's first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Home Care and Hospice Services, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is powered by a talented and dedicated workforce of more than 40,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2018, Penn Medicine provided more than $525 million to benefit our community.

University of Pennsylvania School of Medicine

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.